The success story of indolent disease treatment expanded to difficult-to-treat patient groups
The importance of finding strategies to prevent relapse of acute myeloid leukemia (AML)
Upcoming trials for DLBCL: R-CHOP with acalabrutinib and obinutuzumab with checkpoint inhibitor
General principles of acute lymphoblastic leukemia
How is the landscape of Hodgkin lymphoma therapy changing?